Show simple item record

dc.contributor.authorMorrisroe, K
dc.contributor.authorStevens, W
dc.contributor.authorHuq, M
dc.contributor.authorSahhar, J
dc.contributor.authorNgian, GS
dc.contributor.authorZochling, J
dc.contributor.authorRoddy, J
dc.contributor.authorProudman, S
dc.contributor.authorNikpour, M
dc.contributor.authorHill, C
dc.contributor.authorLester, S
dc.contributor.authorNash, P
dc.contributor.authorRischmueller, M
dc.contributor.authorStrickland, G
dc.contributor.authorThakkar, V
dc.contributor.authorWalker, J
dc.description.abstractBackground: We aimed to evaluate the construct validity of the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) in Australian systemic sclerosis (SSc) patients. Methods: SSc patients, identified through the Australian Scleroderma Cohort Study database, completed two quality-of-life instruments concurrently, the PROMIS-29 and the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). The construct validity of the PROMIS-29 was assessed by the correlations between the PROMIS-29 and the SF-36 and Health Assessment Questionnaire Disability Index (HAQ-DI). Cronbach’s alpha was used to test the internal reliability of all instruments in Australian SSc patients and non-parametric correlation, including Spearman’s correlation, was used to test the construct validity of PROMIS-29 against the SF-36 and HAQ-DI. Results: A total of 477 completed questionnaires were returned, equating to a response rate of 59.6%. The mean (±SD) age of respondents at the time of the survey was 64.1 (±11.1) years. They were predominantly female (87.4%), with limited disease subtype (lcSSc) (77.8%) and long disease duration from onset of first non-Raynaud’s phenomenon symptom at the time of survey (10.9 ± 11.1 years). For the correlation analysis between the PROMIS-29 and the legacy instruments, all Spearman correlation coefficients were in the logical direction and highly significant suggesting that the PROMIS-29 is a good alternative to other validated measures of disease burden. Conclusions: Our study indicates that the PROMIS-29 questionnaire is a valid instrument for measuring healthrelated quality of life in Australian females with lcSSc of long duration.en_US
dc.publisherSAGE Publicationsen_US
dc.relation.ispartofjournalJournal of Scleroderma and Related Disordersen_US
dc.titleValidity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosisen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationMorrisroe, K; Stevens, W; Huq, M; Sahhar, J; Ngian, GS; Zochling, J; Roddy, J; Proudman, S; Nikpour, M; Hill, C; Lester, S; Nash, P; Rischmueller, M; Strickland, G; Thakkar, V; Walker, J, Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis, Journal of Scleroderma and Related Disorders, 2017, 2 (3), pp. 188-195en_US
gro.hasfulltextNo Full Text
gro.griffith.authorNash, Peter

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record